Sodium Valproate Market Research Report 2024 | Valuates Reports

Sodium Valproate market was valued at US$ 167 million in 2023 and is anticipated to reach US$ 252.5 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.

Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-9F7142/Global_Sodium_Valproate_Market_Insights_Forecast_to_2028

Sodium Valproate Market Trends

The growing frequency of neurological illnesses throughout the world is one of the main reasons propelling the expansion of the sodium valproate market. The increasing prevalence of epilepsy and bipolar disorder is driving up demand for sodium valproate, a drug used largely to treat these illnesses. In particular, millions of people throughout the world suffer with epilepsy; the World Health Organization (WHO) estimates that 50 million people worldwide suffer from this illness.

Bipolar disorder, which is characterized by mood swings between manic and depressed episodes, is also becoming more common. More people are seeking treatment as neurological illnesses become more widely recognized and diagnostic tools advance, which is fueling the market for sodium valproate.

Innovations in formulation and technology that enhance medication delivery and patient outcomes are also driving the sodium valproate market. Pharmaceutical firms are spending money on R&D to create novel sodium valproate formulations and dosage forms that will benefit patients by being more convenient, safe, and effective. For example, once-daily dosage is made possible by extended-release formulations, which improve medicine adherence and lessen the frequency of adverse effects brought on by abrupt changes in blood level.

For patients who have trouble swallowing traditional pills, new delivery methods including controlled-release capsules, dispersible tablets, and oral solutions provide an alternative. Pharmaceutical firms are utilizing formulation developments and technology advancements to broaden the market reach of sodium valproate.

By Type
• Injection
• Tablet
• Liquid

By Application
• Epilepsy
• Migraines

Key Companies:
Sanofi, AbbVie, Athenex, Fresenius Kabi, Hikma Farmaceutica, Desitin Pharmaceuticals, Wockhardt, Zentiva

View Full Report: https://reports.valuates.com/market-reports/QYRE-Auto-9F7142/global-sodium-valproate

Email Id:
Please reach us at sales@valuates.com

Address:
Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.